Literature DB >> 16820911

Prognostic role of the tumor-associated tissue inflammatory reaction in transitional bladder cell carcinoma.

Tommaso Cai1, Gabriella Nesi, Vieri Boddi, Sandra Mazzoli, Maurizio Dal Canto, Riccardo Bartoletti.   

Abstract

Many authors have indicated that the presence of an inflammatory response within the tumor may predict not only recurrence and progression but also survival in several tumors, including transitional cell carcinoma (TCC) of the urinary bladder. Several studies have been performed with a mean follow-up period that is often too limited for predicting patient outcome. The aim of the present study was to define the influence of inflammatory cell infiltrate on recurrence, progression and survival in TCC of the bladder over a long follow-up period. Between January and December 1995, 410 consecutive patients, who had undergone transurethral or open surgery for bladder tumors at the same urologic center, were selected for the study. All cases were reviewed to assess histotype, stage and grade of the tumor and presence or absence of tumor-associated inflammatory reaction. To better evaluate the prognostic role of each single factor in TCC, a follow-up of 10 years after surgery was performed. Pathologic evaluation showed superficial TCC in 312 patients, while 98 had an invasive bladder tumor. Three among 410 bladder tumors were squamous cell carcinomas. Out of 407 TCCs, 119 (29.23%) presented inflammation within the tumor or the lamina propria. At 10 years follow-up, a statistically significant association was shown between the presence of inflammation within the tumor or lamina propria and the number of recurrences (p<0.0001). Moreover, the absence of inflammatory infiltrate in the tumor established the relative risk of suffering more than one recurrence at 2.287 (95% CI 1.180-3.346). The Mann-Whitney test confirmed a statistically significant difference between superficial bladder tumors with inflammation and those without (26.3 vs 11.5 months, p<0.001). In terms of survival rate, a statistically significant difference was reported between carcinomas with and without inflammation (p=0.0261). On multivariate analysis, the presence of inflammation within the tumor was found to be an independent predictor of survival in patients with TCC of the bladder (p=0.027). Survival analysis by means of the Kaplan-Meier curves showed a statistically significant difference between patients with tumor-associated inflammatory reaction and those without (p=0.0098). These results confirm that the presence of inflammatory reaction has a good prognostic value in transitional bladder cell carcinoma. However, to better define its prognostic significance, the characterization of inflammatory cells in tumor-associated tissue reaction must be accomplished.

Entities:  

Mesh:

Year:  2006        PMID: 16820911

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  15 in total

1.  Knockdown of PLCε inhibits inflammatory cytokine release via STAT3 phosphorylation in human bladder cancer cells.

Authors:  Xue Yang; Liping Ou; Min Tang; Yin Wang; Xiaorong Wang; E Chen; Jianjun Diao; Xiaohou Wu; Chunli Luo
Journal:  Tumour Biol       Date:  2015-07-09

2.  An immunosuppressive scoring system to predict recurrence and assist in decision regarding postoperative adjuvant treatment in gastric cancer.

Authors:  Jiabin Wang; Qingzhu Qiu; Ningzi Lian; Huagen Wang; Qiaoling Zheng; Yinghong Yang; Yubin Ma; Yajun Zhao; Ping Li; Jianxian Lin; Jun Lu; Qiyue Chen; Longlong Cao; Mi Lin; Changming Huang; Jianwei Xie
Journal:  Am J Cancer Res       Date:  2022-05-15       Impact factor: 5.942

3.  Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer.

Authors:  Yeonjoo Choi; Jin Won Kim; Kyung Han Nam; Song-Hee Han; Ji-Won Kim; Sang-Hoon Ahn; Do Joong Park; Keun-Wook Lee; Hye Seung Lee; Hyung-Ho Kim
Journal:  Gastric Cancer       Date:  2016-09-24       Impact factor: 7.370

4.  Correlation of tumor-associated macrophages and NK cells with bladder cancer size and T stage in patients with solitary low-grade urothelial carcinoma.

Authors:  Kristian Krpina; Emina Babarović; Josip Španjol; Gordana Đorđević; Tobias Maurer; Nives Jonjić
Journal:  Wien Klin Wochenschr       Date:  2015-12-11       Impact factor: 1.704

5.  Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer.

Authors:  Ole Audun Werner Haabeth; Kristina Berg Lorvik; Clara Hammarström; Ian M Donaldson; Guttorm Haraldsen; Bjarne Bogen; Alexandre Corthay
Journal:  Nat Commun       Date:  2011       Impact factor: 14.919

6.  Mandatory role of proteinase-activated receptor 1 in experimental bladder inflammation.

Authors:  Ricardo Saban; Michael R D'Andrea; Patricia Andrade-Gordon; Claudia K Derian; Igor Dozmorov; Michael A Ihnat; Robert E Hurst; Carole A Davis; Cindy Simpson; Marcia R Saban
Journal:  BMC Physiol       Date:  2007-03-30

7.  A model for cancer-suppressive inflammation.

Authors:  Ole Audun Werner Haabeth; Bjarne Bogen; Alexandre Corthay
Journal:  Oncoimmunology       Date:  2012-10-01       Impact factor: 8.110

8.  Regulatory network of inflammation downstream of proteinase-activated receptors.

Authors:  Ricardo Saban; Michael R D'Andrea; Patricia Andrade-Gordon; Claudia K Derian; Igor Dozmorov; Michael A Ihnat; Robert E Hurst; Cindy Simpson; Marcia R Saban
Journal:  BMC Physiol       Date:  2007-03-30

9.  Transcription factor network downstream of protease activated receptors (PARs) modulating mouse bladder inflammation.

Authors:  Ricardo Saban; Cindy Simpson; Carole A Davis; Igor Dozmorov; Julie Maier; Ben Fowler; Michael A Ihnat; Robert E Hurst; Barry K Wershil; Marcia R Saban
Journal:  BMC Immunol       Date:  2007-08-17       Impact factor: 3.615

10.  Cellular profile of the peritumoral inflammatory infiltrate in squamous cells carcinoma of oral mucosa: Correlation with the expression of Ki67 and histologic grading.

Authors:  Fabricio L D Vieira; Beatriz J Vieira; Marco A M Guimaraes; Fernando M Aarestrup
Journal:  BMC Oral Health       Date:  2008-09-02       Impact factor: 2.757

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.